Bevacizumab and cetuximab for metastatic colorectal cancer

Appeal

The Institute has received two appeals from Merck Pharmaceuticals and Bowel Cancer UK & Cancerbacup (joint appeal) against the Final Appraisal Determination and Guidance on this technology. against the Final Appraisal Determination and Guidance on this technology.

As set out in the Guidance for Appellants members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing. The number of observers admitted to the hearing will be limited to a number appropriate for the venue, and priority will be given to members of the public who are not employed by the appellant(s).

A hearing will be held at (MidCity Place, 71 High Holborn, WC1V 6NA) on Monday 27 November starting at 10.00am.

Members of the public will be able to register to attend the appeal hearing using this page from Tuesday 24 October. The Institute will not accept early requests to attend.

The name(s) of the appellant(s) will be published on this page on the day of the appeal. The Institute will not comment on speculation as to the identity of appellants prior to publication of this information on the Institute's website.